Search results
Results from the WOW.Com Content Network
Survival rates for treated esthesioneuroblastoma are best for surgery with radiotherapy (65%), then for radiotherapy and chemotherapy (51%), just surgery (48%), surgery, radiotherapy and chemotherapy (47%) and finally just radiotherapy (37%). [14] From the literature, radiotherapy and surgery seem to boast the best outcome for patients.
By data from England, the overall 5-year survival rate of neuroblastoma is 67%. [59] Between 20% and 50% of high-risk cases do not respond adequately to induction high-dose chemotherapy and are progressive or refractory. [60] [61] Relapse after completion of frontline therapy is also common. Further treatment is available in phase I and phase ...
The age-adjusted incidence rate is 6.4 per 100,000 per year, and the death rate is 4.3 per 100,000 per year. The lifetime risk of developing brain cancer for someone born today is 0.60%. Only around a third of those diagnosed with brain cancer survive for five years after diagnosis.
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
Small cell lung cancer has a five-year survival rate of 4% according to Cancer Centers of America's Website. [5] The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
Upon analysis, scientists found that participants who stayed on standard statin treatment for their lifetime increased their quality-adjusted life years by 0.24-0.70, and those on higher-intensity ...
Among over a thousand persons aged 40 years and older, 12.0% reported a problem with smell in the past 12 months and 12.4% had olfactory dysfunction on examination. Prevalence rose from 4.2% at age 40–49 to 39.4% at 80 years and older and was higher in men than women, in blacks and Mexican Americans than in whites and in less than more educated.